Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant

被引：0

作者：

Kitko, Carrie L. ^{[1
]}

Braun, Thomas ^{[2
]}

Schuler, Charles ^{[3
]}

Choi, Sung Won ^{[1
]}

Yanik, Gregory ^{[1
]}

Pawarode, Attaphol ^{[4
]}

Magenau, John ^{[4
]}

Taylor, Austin ^{[5
]}

Ferrara, James L. M. ^{[5
]}

Couriel, Daniel R. ^{[4
]}

Levine, John ^{[1
]}

机构：

[1] Univ Michigan, Pediat Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[4] Univ Michigan, Adult Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期

关键词：

D O I：

10.1016/j.bbmt.2014.11.537

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

490

引用

页码：S337 / S337

页数：1

共 50 条

[21] A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results
Schroeder, Mark A.
Choi, Jaebok
Cooper, Matthew L.
Schwab, David
Willey, Sarah
Liu, Jingxia
Holt, Matthew
Eissenberg, Linda
Pusic, Iskra
Ghobadi, Armin
Romee, Rizwan
Welch, John S.
Stockerl-Goldstein, Keith
Abboud, Camille N.
Vij, Ravi
Uy, Geoffrey L.
Westervelt, Peter
Dipersio, John F.
BLOOD, 2015, 126 (23)
[22] POST TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN PATIENTS RECEIVING HLA MISMATCHED (7/8) UNRELATED DONOR FOR MYELOID MALIGNANCIES: RESULTS OF THE GITMO PROSPECTIVE PHYLOS TRIAL
Raiola, Anna Maria
Bruno, Benedetto
Risitano, Antonio Maria
Mosna, Federico
Cavattoni, Irene Maria
Onida, Francesco
Saporiti, Giorgia
Patriarca, Francesca
Battista, Marta Lisa
Pavone, Vincenzo
Mele, Anna
Chiusolo, Patrizia
Sica, Simona
Loteta, Barbara
Di Grazia, Carmen
Carella, Angelo Michele
Salvatore, Dalila
Morello, Enrico
Leoni, Alessandro
Giaccone, Luisa
Bernasconi, Paolo
Terruzzi, Elisabetta
Mordini, Nicola
Borghero, Carlo
Zallio, Francesco
Narni, Franco
Grassi, Anna
Olivieri, Attilio
Vacca, Adriana
Sacchi, Nicoletta
Ciccone, Giovannino
Castiglione, Anna
Angelucci, Emanuele
Bonifazi, Francesca
Ciceri, Fabio
Degrandi, Eliana
Martino, Massimo
BONE MARROW TRANSPLANTATION, 2024, 59 : 306 - 307
[23] GVHD prophylaxis with cyclosporine plus mycophenolate mofetil improves outcome compared to cyclosporine alone in patients receiving reduced intensity conditioning hematopoietic stem-cell transplantation from unrelated donor for hematological diseases
Brissot-Davaine, Eolia
Moreau, Philippe
Ayari, Sameh
Delaunay, Jacques
Guillaume, Thierry
Pelletier, Jean-Baptiste
Harousseau, Jean-Luc
Chevallier, Patrice
BLOOD, 2007, 110 (11) : 323B - 323B
[24] Results of the Blood and Marrow Transplant Clinical Trials Network Study BMT CTN 0601: Scurt - a Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation (BMT) for Children with Severe Sickle Cell Disease
Shenoy, Shalini
Eapen, Mary
Wu, Juan
Walters, Mark C.
Levine, John E.
Logan, Brent R.
Gersten, Iris D.
Kamani, Naynesh R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S104 - S104
[25] A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation
Al Malki, Monzr M.
Tsai, Ni-Chun
Palmer, Joycelynne
Mokhtari, Sally
Cao, Thai
Ali, Haris
Salhotra, Amandeep
Arslan, Shukaib
Aldoss, Ibrahim
Karras, Nicole
Zain, Jasmine
Khaled, Samer K.
Stein, Anthony S.
Snyder, David S.
Marcucci, Guido
Forman, Stephen J.
Nademanee, Auayporn
Nakamura, Ryotaro
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S188 - S188
[26] Improved survival following reduced-intensity cord blood transplantation using GvHD prophylaxis of tacrolimus plus mycophenolate mofetil compared to tacrolimus alone
Uchida, N.
Wake, A.
Nishida, A.
Ota, H.
Kon, A.
Karasawa, M.
Shimazu, H.
Ikebe, T.
Nakano, N.
Ishiwata, K.
Yamamoto, H.
Asano-Mori, Y.
Izutsu, K.
Araoka, H.
Yoneyama, A.
Makino, S.
Taniguchi, S.
BONE MARROW TRANSPLANTATION, 2011, 46 : S290 - S290
[27] Hydroxychloroquine for the prevention of acute graft versus host disease (GVHD) in unrelated donor (URD) transplantation: Preliminary results of a phase II trial.
Khoury, H
Adkins, D
Young, S
Shenoy, S
Haug, J
Westervelt, P
Vij, R
Brown, R
Goodnough, LT
DiPersio, JF
BLOOD, 1998, 92 (10) : 450A - 450A
[28] Hydroxychloroquine for the prevention of acute graft-versus-host disease (GVHD) in unrelated donor (URD) transplantation: Update of a phase II trial.
Khoury, H
Adkins, D
Pence, H
Shenoy, S
Haug, J
Todd, G
Westervelt, P
Vij, R
Brown, R
Goodnough, LT
DiPersio, JF
BLOOD, 1999, 94 (10) : 153A - 153A
[29] Phase I clinical trial of donor T-helper Type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant
Fowler, D
Hou, J
Foley, J
Hakim, F
Odom, J
Castro, K
Carter, C
Read, E
Gea-Banacloche, J
Kasten-Sportes, C
Kwak, L
Wilson, W
Levine, B
June, C
Gress, R
Bishop, M
CYTOTHERAPY, 2002, 4 (05) : 429 - 430
[30] Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant
Bashir, Qaiser
Munsell, Mark F.
Giralt, Sergio
Silva, Leandro de Padua
Sharma, Manish
Couriel, Daniel
Chiattone, Alexandre
Popat, Uday
Qazilbash, Muzaffar H.
Fernandez-Vina, Marcelo
Champlin, Richard E.
de Lima, Marcos J.
LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 915 - 919

← 1 2 3 4 5 →